Study Suggests Lung Cancer Screening Criteria May Not Capture All Smokers Who Need It

Article

Eligibility criteria set for coverage of low-dose computed tomography for individuals deemed at high risk for lung cancer may actually exclude many potential lung cancer patients who would benefit from screening, according to a new study.

Eligibility criteria set by the Centers for Medicare & Medicaid Services (CMS) for coverage of low-dose computed tomography (LDCT) for individuals deemed at high risk for lung cancer may actually exclude many potential lung cancer patients who would benefit from screening, according to a new study.

The findings, published in the Journal of the American Medical Association, indicate that efforts to get long-term smokers to quit in recent decades make some former long-term smokers ineligible for screening, because they have not smoked for more than 15 years.

In the study, by Ping Yang MD, and colleagues at the Mayo Clinic in Rochester, Minn., researchers evaluated trends in the proportion of patients with lung cancer who meet the US Preventive Services Task Force (USPSTF) criteria as being at high risk for lung cancer. CMS used the USPSTF criteria as the basis for its coverage determination.

Researchers looked at 140,000 residents in Olmstead County, Minn., aged 20 or older, from 1984 through 2011. All confirmed cases of lung cancer were identified using the Rochester Epidemiology Project database, adjusting for age and gender distribution in the US population in 2000.

The proportion of cases meeting USPSTF criteria was identified and represented asymptomatic adults aged 55 to 80 years with a 30 pack—year smoking history. This means the person smoked the equivalent of one pack a day for 30 years; a person could also have smoked two packs a day for 15 years. To be screened, a person must be a current smoker or have quit within the past 15 years. Under the Medicare criteria, the age cutoff for LDCT coverage is 77 years.

Researchers identified 1351 patients with a new diagnosis of primary lung cancer between 1984 and 2011. However, the proportion of patients with lung cancer who smoked more than 30 pack-years declined, and the proportion of former smokers, especially those who quit more than 15 years ago, increased.

Of note, the share of lung cancer patients meeting the USPSTF criteria declined over time, with 57 percent of patients eligible for screening from 1984 to 1990 and only 43 percent eligible from 2005 to 2011. The drop-off in eligibility was greater among women—from 52 percent to 37 percent; for men the drop-off was 60 percent to 50 percent.

“Our findings may reflect a temporal change in smoking patterns in which the proportion of adults with a 30 pack—year smoking history and having quit within 15 years declined,” the authors write. “The decline in the proportion of patients meeting USPSTF high-risk criteria indicates that an increasing number of patients with lung cancer would not have been candidates for screening. More sensitive screening criteria may need to be identified while balancing the potential harm from computed tomography.”

CMS’ decision to screen current and former smokers for lung cancer was based on the results of the National Lung Screening Protocol Trial Protocol, which found that patients who received screening had a 15% to 20% lower risk of dying from lung cancer; results published in 2013 showed that targeting screening toward those at greatest risk produced the most effective results.

Related Videos
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey.  If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key.  “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained.  READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Yuliya P.L Linhares, MD, an expert on CLL
Yuliya P.L Linhares, MD, and Josie Montegaard, MSN, AGPCNP-BC, experts on CLL
Image of a man with a beard.
Image of a man with gray facial hair and a navy blue suit with a light orange tie.
Image of a woman with black hair.
Related Content